Skip to content

GSK

GSK Plc

NYSE · Healthcare · Drug Manufacturers - General · GB

$50.22
−1.65%
Ask drillr

Year over year

Reported trailing growth

Revenue
EBITDA
EBIT
EPS
Free cash flow
Operating cash flow

Forward estimates

Based on analyst estimates

Revenue
+5.4%
EBITDA
+64.6%
EPS
+56.7%

Three-year CAGR

Revenue
+3.7%
EBITDA
+6.5%
EBIT
+9.0%
Net income
-27.4%
EPS
-27.6%
Free cash flow
-4.8%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026